SUMMARYMxra8 is a recently described receptor for multiple alphaviruses, including Chikungunya (CHIKV), Mayaro (MAYV), Ross River (RRV), and O’nyong nyong (ONNV) viruses. To determine its role in pathogenesis, we generated mice with mutant Mxra8 alleles: an 8-nucleotide deletion that produces a truncated, soluble form (Mxra8Δ8/Δ8) and a 97-nucleotide deletion that abolishes Mxra8 expression (Mxra8Δ97/Δ97). Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 fibroblasts show reduced CHIKV infection in culture, and Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 mice have decreased infection of musculoskeletal tissues with CHIKV, MAYV, RRV, or ONNV. Less foot swelling is observed in CHIKV-infected Mxra8 mutant mice, which correlated with fewer infiltrating neutrophils and cytokines. A recombinant E2-D71A CHIKV with diminished binding to Mxra8 is attenuated in vivo in wild-type mice. Ectopic Mxra8 expression is sufficient to enhance CHIKV infection and lethality in transgenic flies. These studies establish a role for Mxra8 in the pathogenesis of multiple alphaviruses and suggest that targeting this protein may mitigate diseasein humans.
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes explosive epidemics of a febrile illness characterized by debilitating arthralgia and arthritis that can endure for months to years following infection. In mouse models, CHIKV persists in joint tissues for weeks to months and is associated with chronic synovitis. Using a recombinant CHIKV strain encoding a CD8+ T cell receptor epitope from ovalbumin, as well as a viral peptide-specific major histocompatibility complex class I tetramer, we interrogated CD8+ T cell responses during CHIKV infection. Epitope-specific CD8+ T cells, which were reduced in Batf3−/− and Wdfy4−/− mice with known defects in antigen cross-presentation, accumulated in joint tissue and the spleen. Antigen-specific ex vivo restimulation assays and in vivo killing assays demonstrated that CD8+ T cells produce cytokine and have cytolytic activity. Despite the induction of a virus-specific CD8+ T cell response, the CHIKV burden in joint-associated tissues and the spleen were equivalent in wild-type (WT) and CD8α−/− mice during both the acute and the chronic phases of infection. In comparison, CD8+ T cells were essential for the control of acute and chronic lymphocytic choriomeningitis virus infection in the joint and spleen. Moreover, adoptive transfer of virus-specific effector CD8+ T cells or immunization with a vaccine that induces virus-specific effector CD8+ T cells prior to infection enhanced the clearance of CHIKV infection in the spleen but had a minimal impact on CHIKV infection in the joint. Collectively, these data suggest that CHIKV establishes and maintains a persistent infection in joint-associated tissue in part by evading CD8+ T cell immunity. IMPORTANCE CHIKV is a reemerging mosquito-transmitted virus that in the last decade has spread into Europe, Asia, the Pacific Region, and the Americas. Joint pain, swelling, and stiffness can endure for months to years after CHIKV infection, and epidemics have a severe economic impact. Elucidating the mechanisms by which CHIKV subverts antiviral immunity to establish and maintain a persistent infection may lead to the development of new therapeutic strategies against chronic CHIKV disease. In this study, we found that CHIKV establishes and maintains a persistent infection in joint-associated tissue in part by evading antiviral CD8+ T cell immunity. Thus, immunomodulatory therapies that improve CD8+ T cell immune surveillance and clearance of CHIKV infection could be a strategy for mitigating chronic CHIKV disease.
Highlights d An insertion in Bovinae Mxra8 sterically blocks alphavirus binding and infection d The sequence insertion evolved in the Miocene epoch at least 5 million years ago d Loss of the insertion in Mxra8 in several Bovinae restores alphavirus infection d Introduction of the insertion into Mxra8 of mice prevents alphavirus pathogenesis
Arthritogenic alphaviruses have infected millions of people globally. Following acute infection, symptoms of joint pain, swelling, and stiffness can last for months or even years, likely due to persistence of viral RNA and antigen, which also is seen in mice. Intriguingly, wild-type and CD8−/− mice show a similar lack of clearance of viral RNA. Despite this, a mechanism for this CD8+ T cell evasion has not been identified. We hypothesized that there are defects in the generation, function, and migration of the CD8+ T cells after infection with Ross River virus (RRV), a prototype, arthritogenic alphavirus. To study the antigen-specific response, we used a genetically modified RRV expressing the lymphocytic choriomeningitis virus (LCMV)-derived gp33 peptide. Compared to LCMV infection, in which CD8+ T cells are required for viral clearance, RRV infection generates fewer gp33-specific CD8+ T cells in the spleen and draining lymph node, especially at early times after infection. Antigen-specific CD8+ T cells from the draining lymph node at 5 days after RRV infection express much less granzyme B than in LCMV-infected mice. In vivo cytolysis assays showed a qualitative difference in CD8+ T cell killing of targets especially when variant peptides were used for pulsing. Finally, intravital imaging revealed that while both RRV and LCMV infection recruit CD8+ T cells and retain them in an antigen specific manner near infected cells, CD8+ T cells appear to have less contact with RRV than LCMV-infected cells. Identification of a specific defect in the CD8+ T cell response to arthritogenic alphaviruses would increase our understanding of viral immune evasion and provide a target for therapy of these debilitating infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.